Peregrine Capital Management LLC Buys Shares of 96,306 Collegium Pharmaceutical, Inc. $COLL

Peregrine Capital Management LLC purchased a new stake in shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL) in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 96,306 shares of the specialty pharmaceutical company’s stock, valued at approximately $3,185,000.

Other institutional investors have also recently made changes to their positions in the company. Janus Henderson Group PLC boosted its holdings in shares of Collegium Pharmaceutical by 59.1% in the fourth quarter. Janus Henderson Group PLC now owns 1,448,578 shares of the specialty pharmaceutical company’s stock worth $67,026,000 after buying an additional 538,337 shares during the last quarter. Massachusetts Financial Services Co. MA increased its holdings in Collegium Pharmaceutical by 65.3% during the fourth quarter. Massachusetts Financial Services Co. MA now owns 1,312,655 shares of the specialty pharmaceutical company’s stock valued at $60,776,000 after buying an additional 518,721 shares during the last quarter. Millennium Management LLC raised its position in Collegium Pharmaceutical by 248.5% in the first quarter. Millennium Management LLC now owns 647,832 shares of the specialty pharmaceutical company’s stock worth $19,338,000 after acquiring an additional 461,914 shares during the period. Assenagon Asset Management S.A. raised its position in Collegium Pharmaceutical by 161.6% in the fourth quarter. Assenagon Asset Management S.A. now owns 511,698 shares of the specialty pharmaceutical company’s stock worth $23,692,000 after acquiring an additional 316,109 shares during the period. Finally, Two Sigma Investments LP boosted its stake in shares of Collegium Pharmaceutical by 897.2% during the 3rd quarter. Two Sigma Investments LP now owns 269,318 shares of the specialty pharmaceutical company’s stock worth $9,423,000 after acquiring an additional 242,310 shares during the last quarter.

Collegium Pharmaceutical Stock Performance

COLL opened at $37.03 on Friday. The company has a 50 day simple moving average of $34.28 and a two-hundred day simple moving average of $39.28. The company has a debt-to-equity ratio of 2.47, a current ratio of 1.71 and a quick ratio of 1.62. The firm has a market cap of $1.20 billion, a P/E ratio of 18.15 and a beta of 0.73. Collegium Pharmaceutical, Inc. has a 1-year low of $29.19 and a 1-year high of $50.79.

Collegium Pharmaceutical (NASDAQ:COLL) last announced its quarterly earnings data on Thursday, May 7th. The specialty pharmaceutical company reported $1.76 EPS for the quarter, beating the consensus estimate of $1.52 by $0.24. Collegium Pharmaceutical had a net margin of 9.41% and a return on equity of 95.18%. The firm had revenue of $193.52 million for the quarter, compared to the consensus estimate of $184.47 million. During the same period last year, the firm earned $1.49 EPS. The company’s revenue was up 8.9% on a year-over-year basis. Equities analysts forecast that Collegium Pharmaceutical, Inc. will post 6.76 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently commented on the company. Wall Street Zen upgraded Collegium Pharmaceutical from a “buy” rating to a “strong-buy” rating in a research note on Saturday, May 9th. Weiss Ratings downgraded Collegium Pharmaceutical from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Thursday, March 5th. Truist Financial raised Collegium Pharmaceutical to a “strong-buy” rating in a report on Monday, June 15th. Zacks Research upgraded Collegium Pharmaceutical from a “hold” rating to a “strong-buy” rating in a research report on Monday. Finally, Needham & Company LLC reaffirmed a “buy” rating and issued a $56.00 price objective (up from $54.00) on shares of Collegium Pharmaceutical in a research note on Thursday, March 19th. Two equities research analysts have rated the stock with a Strong Buy rating, three have given a Buy rating and one has given a Hold rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Buy” and an average target price of $57.50.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc is a specialty pharmaceutical company focused on the development, manufacture and commercialization of products for pain management and opioid dependence. The company’s core expertise lies in its DETERx microsphere technology, a platform designed to provide extended-release delivery of active pharmaceutical ingredients while deterring manipulation for unintended routes of abuse.

The company’s principal marketed products include Xtampza® ER (extended-release oxycodone), which received approval from the U.S.